Measuring plasma PCSK9 may ID resistance to PCSK9 inhibitors

November 29, 2017

(HealthDay)—Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) may help assess apparent resistance to PCSK9 inhibitors, according to a research letter published online Nov. 28 in the Annals of Internal Medicine.

Michael D. Shapiro, D.O., from the Oregon Health & Science University in Portland, and colleagues describe changes in PCSK9 levels before and after PCSK9 inhibitor therapy in 17 adult patients with cardiovascular disease (14 patients) and/or familial hypercholesterolemia (nine patients). Before and three months after initiation of PCSK9 inhibitor therapy, total plasma PCSK9 levels were measured.

The researchers found that the mean baseline plasma PCSK9 level was 324 ng/mL. Within five days of their sixth self-injection, the total plasma PCSK9 levels were 2,286 ng/mL in patients with the anticipated greater-than-45-percent reduction in (LDL) levels (median seven-fold increase from baseline levels). Plasma PCSK9 levels varied, but they increased by at least 3.7-fold in 16 of the patients; pre- and post-treatment values were not overlapping for any of these patients. Two of the patients with familial hypercholesterolemia had markedly attenuated response of LDL cholesterol levels to the PCSK9 inhibitor; one of these had no change in plasma PCSK9 levels.

"We report a simple method for assessing apparent resistance by measuring total levels of plasma PCSK9 before and after treatment," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Explore further: PCSK9 increased in females, youth with type 1 diabetes

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

PCSK9 increased in females, youth with type 1 diabetes

June 20, 2017
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) is increased in young females and youth with type 1 diabetes (T1D), according to research published online June 6 in Diabetes Care.

PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis

August 28, 2017
PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class of cholesterol lowering ...

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

PCSK9 inhibitors reduce lipoprotein (a) production

October 31, 2016
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

August 22, 2017
An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater ...

Recommended for you

Study reveals new link between atrial fibrillation and mutations in heart disease gene

December 11, 2018
Atrial fibrillation (Afib), a heart condition that causes a rapid, irregular heartbeat that increases a person's risk of stroke and heart failure, is fairly common among older adults. However, its early onset form is relatively ...

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Study: Age, race differences determine risk of stroke in women and men

December 11, 2018
A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, ...

Possible connection between cardiovascular disease and living near oil and gas wells

December 11, 2018
Researchers at the Colorado School of Public Health have found a possible connection between the intensity of oil and gas exploration in an area and early indicators of cardiovascular disease among nearby residents.

Study links frequent red meat consumption to high levels of chemical associated with heart disease

December 11, 2018
Researchers have identified another reason to limit red meat consumption: high levels of a gut-generated chemical called trimethylamine N-oxide (TMAO), that also is linked to heart disease. Scientists found that people who ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.